Anejaculation is a rare cause of infertility and adversely affects the general sense of well-being and perception of sexual life satisfaction. Evidence to support effective and noninvasive treatment for this ejaculatory disorder is lacking. This study aimed to evaluate the efficacy and safety of midodrine (a 1 -adrenergic receptor agonist) for the treatment of organic anejaculation but not spinal cord injury (SCI). A total of 128 patients were randomly assigned to oral midodrine 7.5-15 mg per day in a stepwise approach (group 1, n ¼ 64), or a similar regimen of placebo (group 2, n ¼ 64). They underwent a complete physical examination, echocardiography, 12-lead electrocardiogram, transrectal ultrasonography, complete blood count and blood chemistry. Hormonal assays included serum levels of luteinizing hormone, follicle-stimulating hormone, prolactin and testosterone. To rule out other sexual dysfunction, patients also completed the International Index of Erectile Function questionnaire. Psychiatric disorders were excluded by appropriate tests. Outcome measure was reversal of the anejaculation. None of the patients in the placebo group achieved antegrade or retrograde ejaculation. At the end of study, antegrade, retrograde and antegrade þ retrograde ejaculation occurred in 18 (29.5%), 8 (13.1%) and 9 (14.8%) patients in midodrine group, respectively (all P ¼ 0.01). The most and least favorable responses were among patients with multiple sclerosis and bilateral sympathectomy, respectively. Midodrine improved ejaculation function in a dose-dependent manner. Four participants (6.3%) in midodrine group discontinued this study for reasons of adverse events. In patients with organic anejaculation but without SCI midodrine can reverse anejaculation in more than 50% of patients. Further studies are needed, however, for the evaluation of different treatment regimens in anejaculation therapy.
Introduction
Anejaculation is defined as complete absence of antegrade or retrograde ejaculation. It is a rare disorder in men (1-4% of sexually active men) 1 that can cause male factor infertility and considerable distress. Anejaculation can be classified as lifelong or acquired subtypes based on the developmental history. Ejaculation is a reflex comprising afferent and efferent pathways. Afferent stimuli pass through the penile dorsal nerve into the spinothalamic tract and to the thalamus and sensory cortex. The efferent signals run through the anterolateral column of the sympathetic ganglia at T12-L3. From here, sympathetic efferent fibers traverse to the pelvic plexus through the hypogastric nerves. Stimuli from pelvic plexus, cause sequential contraction of the epididymis, vas deferens, seminal vesicle and prostate, with closure of the bladder neck (emission). After expulsion of ejaculate into the posterior urethra, pudendal nerve, which originates from sacral spinal cord (S2-S4) causes rhythmic contractions of the bulbospongiosus and bulbocavernosus muscles, and true ejaculation is then initiated. 2 Emission is a sympathetically mediated process, but true ejaculation is somatically mediated event. Failures in the emission lead to anejaculation.
The etiologies of the anejaculation can be categorized into three major groups: organic, psychogenic and drug related. 3 Any psychological or medical disease, surgical procedure or drug, which affects the afferent or efferent nerve supply to the seminal vesicle, vas, bladder neck, posterior urethra or pelvic floor, can result in anejaculation. Psychological factors underlying this condition are poorly understood. Major psychological etiologies regarding the genesis of anejaculation are as follows: strict religious beliefs, lack of sexual or emotional attraction to a female partner, low levels of sexual arousal, idiosyncratic fear of pregnancy or sexually transmissible disease and preference for masturbation over partnered sexual intercourse. 1, 3 Among organic etiologies, are spinal cord injury (SCI), ejaculatory duct obstruction, diabetes mellitus, transverse myelitis and multiple sclerosis.
Many treatments for anejaculation have been proposed, including psychotherapy, medical therapy, rectal probe electroejaculation (EE) and penile vibratory stimulation (PVS). 4 Pharmacologic therapy in non-spinal cord injured patients has been almost exclusively with a-agonistic drugs (imipramine, ephedrine, pseudoephedrine and milodrin). 5 In contrast, parasympathomimetic drugs (physostigmine and neostigmine) almost always have been used in SCI-related anejaculation. Although medical treatment may not always produce normal ejaculation, it may convert a patient with lack of emission into one with partial antegrade ejaculation (AE) or retrograde ejaculation (RE).
More recently, the a 1 -adrenegic agonist midodrine has been proposed to treat RE and anejaculation. Midodrine, 2-amino-N-(2-(2,5-dimethoxy-phenyl)-2-hydroxyethyl), is an a 1 -adrenergic receptor agonist prodrug of desglymidodrine. 6 Midodrine is a wellabsorbed (93%) drug and compared with ephedrine and other sympathomimetic agents, causes lessfrequent and less-severe a-adrenergic effects. 7 Midodrine is widely used in the treatment of various hypotensive disorders. 8 In a recent study, 185 spinal cord injured patients who failed to respond to PSV were treated with midodrine 30-120 min before a new stimulation. 9 Antegrade or retrograde ejaculation occurred in 64.6% of the patients. In another study, ejaculation potential of 62 spinal cord injured men was assessed with various measures. Of patients who did not respond to PVS, 22% were salvaged by midodrine combined with PVS. 10 To the best of our knowledge, there is no published placebo-controlled study on the effect of midodrine in patients with organic anejaculation but without SCI.
Materials and methods

Study participants
From March 2006 through April 2008, one hundred and forty-four non-spinal cord injured patients with organic anejaculation were admitted consecutively for screening. The mean age of the patients was 47.7 ± 9.4 years (range, 35-55 years). This study was approved by the Human Ethics Committee and was conducted according to the Declaration of Helsinki. All were diagnosed as having non-SCI-related organic anejaculation. The absence of spermatozoa and fructose in centrifuged post-coital specimens of voided urine confirms the diagnosis. After providing informed consent, recruited subjects were invited for a test visit. Each subject was administered a 2.5-mg oral dose of midodrine and blood pressure (BP) was measured every 30 min for 4 h. Every subject with exaggerated BP responses to midodrine (BP4140 mm Hg) was excluded. Anejaculation was defined as the complete absence of an antegrade or retrograde ejaculation. All of them have had a period of failed pharmacologic therapy including, imipramine (96, 77.4%), ephedrine (78, 62.9%), pseudoephedrine (86, 69.3%), phenylpropanolamine hydrochloride (58, 46.8%) and neostigmine (29, 23.4%).
Inclusion-exclusion criteria
Only patients with a known cause for their anejaculation state other than SCI were included. Exclusion criteria included the presence of any psychiatric or mental disorders and anxiety; no discernible cause of anejaculation, serious relationship problems; history of alcoholism or other substance abuse; use of any drug that might affect sexual function; concurrent other sexual dysfunction such as erectile dysfunction; and possibility of drug-associated side-effects that could lead to dangerous events in the patients. Patients with a history of arterial hypertension (systolic pressure 4160 mm Hg, diastolic pressure490 mm Hg), ischemic heart disease, or cerebrovascular disease, and participants taking any medications likely to affect blood vessel compliance were excluded from the study.
Evaluations
They were asked about their medical and sexual histories, and underwent a complete physical examination, echocardiography, 12-lead electrocardiogram, 24-h ambulatory BP monitoring, transrectal ultrasonography, complete blood count and blood chemistry. Hormonal assays included serum levels of luteinizing hormone, follicle-stimulating hormone, prolactin and testosterone. To rule out other past and concurrent sexual dysfunction, patients completed the International Index of Erectile Function questionnaire at the screening visit. 11 The diagnosis of organic anejaculation was based on the presence of physical causes for the condition, inability to ejaculate during penetrative sexual intercourse and on the absence of nocturnal emissions. Retrograde ejaculation was ruled out by the absence of sperm in urine analysis. To be able to Midodrine for treating of organic anejaculation MR Safarinejad exclude any psychiatric disorder all patients completed the Dissociative Experiences Scale, 12 the Hamilton Rating Scale for Depression, 13 the Hamilton Rating Scale for Anxiety 14 and the Liebowitz Social Anxiety Scale. 15 Of 144 screened patients, 128 met inclusion-exclusion criteria and consented to proceed with the study protocol.
Treatment protocol
The study was conducted under the supervision of a dietician. Patients were requested to have a diet with moderate salt restriction, avoidance of caffeine, licorice and methylxanthine-containing beverages and foods, and sympathomimetic substances throughout the study period. Patients had discontinued all prescribed medications at least 12 weeks before the study. The study length was 14 weeks and included a 2-week placebo lead-in phase and a 4-week dose titration period, followed by 8 weeks at a stable dose.
Allocation of participants to treatment or placebo groups was performed by a study coordinator, on the basis of a computer-generated random sequence using an interactive voice response system. The coordinator was responsible for the day-to-day management of the trial and keeping the allocation information in the sealed envelope. After 2 weeks of placebo lead-in phase, patients were randomized initially to receive midodrine 2.5 mg 3 times daily (group 1, n ¼ 64) or similar regimen of placebo (group 2, n ¼ 64). During this 4-week dose titration period, patients randomly assigned to midodrine 7.5 mg per day had their dose increased by 2.5 mg per week, as at the end of this period all of the remained subjects in group 1 were receiving midodrine 5 mg 3 times daily. All patients were evaluated every day, which included assessment of symptom status, general medical condition, and documentation of BP and heart rate in the supine position and after 3 min in the upright position. After each dose escalation, participants underwent 24-hour ambulatory BP monitoring. Thereafter, subjects in midodrine group received a stable dose of midodrine 5 mg 3 times daily up to 8 weeks. Patients who could not tolerate a dose of at least 7.5 mg per day of midodrine were discontinued. Patients and investigator were blinded throughout the study to the order of treatment assignment.
Efficacy measures
Participants were followed up every week during 8-week stable dose period. On the visit day of each follow-up point, subjects underwent repeat 24-h ambulatory BP monitoring. In dose escalation and stable dose periods, patients with a systolic blood pressure (SBP) greater than 140 mm Hg or a diastolic blood pressure (DBP) greater than 90 mm Hg were discontinued. Antegrade ejaculation was defined as more than 20 million spermatozoa per ml in the antegrade specimen. Retrograde ejaculation was defined as the presence of spermatozoa in postorgasm urine sample. Outcome measure was reversal of the anejaculation.
Safety assessment
Adverse events were monitored with questionnaires and physical examinations throughout the study.
At each follow-up visit patients were questioned about the presence of any symptoms they experienced. Treatment-emergent adverse events were coded by preferred term (Medical Dictionary for Regulatory Activities, MedDRA) as well as by severity and relation to study drug. Changes from baseline in laboratory values, vital signs and ECG results were assessed.
Statistical analysis
Data are presented as means±s.d. The primary statistical analysis was by intention-to-treat with inclusion of all the patients who had had any assessments after baseline. The last observation carried forward was used for subjects who did not complete the full study protocol. With a ¼ 0.05, b ¼ 0.20 and D ¼ 30% a minimum of 52 subjects per group should complete the trial. The efficacy end points were analyzed by an ANCOVA (analysis of covariance) model with the terms of treatment, and investigator. The incidence of adverse events was compared between the midodrine and the placebo groups by using Fisher's exact test, and the doseeffect relation was evaluated by using the CochranArmitage test. Analyses were performed using SPSS version 10.0 software (SPSS, Chicago, IL, USA) with two-sided a ¼ 0.05 considered significant.
Results
The causes of anejaculation were shown in Table 1 . The baseline clinical and demographic characteristics of the patients that randomized into the study are summarized in Table 1 . One hundred and eleven (87%) participants randomized to the study completed the 8-week stable dose medication period. Reasons for termination before study completion in each group are shown in Figure 1 . The hormonal concentrations of all patients were within normal limits. The results of ejaculation type are shown in Midodrine for treating of organic anejaculation MR Safarinejad patients in midodrine group, respectively (all P ¼ 0.01). At this time, of participants in midodrine group, 26 (42.6%) had anejaculation yet (P ¼ 0.001). Significant differences could be detected between the response rates to midodrine between the different diagnoses ( Table 3) . The most and least favorable responses were among patients with multiple sclerosis and bilateral sympathectomy, respectively (Figure 2) . At the end of study, of patients with multiple sclerosis and bilateral sympathectomy, 14.3 and 66.7%, had anejaculation, and 57.1 and 0%, developed AE, respectively. Individual variations among the groups (as shown in Figure 2 ) suggest that midodrine could benefit 15-65% of the patients. Midodrine improved ejaculation function in a dose-dependent manner (Table 4) . Of patients taking 7.5 mg and 15 mg midodrine, 14.8 and 57.4% had anejaculation reversal success, respectively (P ¼ 0.001) (Figure 3) . Mean ( ± s.d.) values for sperm variables in men with AE were as follows: motility, 62.6 ± 11.4%; progressive motility, 58.6±11.4%; density, 39.2±12.4 Â 10 6 /ml; total sperm count, 75.4 ± 11.4 Â 10 6 /ml; and abnormal sperm morphology, 27.4 ± 8.2%. 
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Adverse events
No remarkable treatment-emergent adverse events of midodrine treatment were recorded. Four participants (6.3%) in midodrine group discontinued this study by reason of adverse events (developing hypertension). Treatment with midodrine increased mean 24-h ambulatory systolic and diastolic blood pressures (Figure 4 ). Mean 24-h ambulatory BP at baseline was 124/67 ± 8/6 mm Hg. During medical treatment with midodrine 15 mg per day, the mean 24-h ambulatory BP was 134/72±7/6 mm Hg, representing a mean 24-h ambulatory BP increase of 10.5 mm Hg (8.1% mean SBP increase, 7.5% mean DBP increase). The difference in mean 24-h ambulatory BP between treatment doses was significant for systolic and diastolic blood pressures (P ¼ 0.03) (Figure 4 ). Mean heart rate at baseline was 67 ± 4 per min. This increased by 20.9% with midodrine 15 mg per day (P ¼ 0.02) ( Figure 5 ).
Discussion
This is the first study on midodrine use in men with organic but non-SCI injury-related anejaculation.
The primary outcome of this study indicates that midodrine, reversed anejaculation in significant numbers of patients. Our relatively high success rate (58% of men achieved antegrade and/or retrograde ejaculation) is probably because of appropriate patients selection. In this study, underlying diagnosis had influence on the success rates of medical treatment. There was a trend toward better outcomes in patients with multiple sclerosis and Parkinson's disease. In an earlier study, 185 spinal cord injured patients with anejaculation who failed to respond to PVS were treated with midodrine 30-120 min before a new stimulation. Antegrade or retrograde ejaculation was achieved in 64.6% of men. 9 Similarly, in another study in 62 men with SCI lesions, ejacula- Midodrine for treating of organic anejaculation MR Safarinejad tion potential was assessed with various sources of stimulation, beginning with natural stimulation, followed, if the test was negative, by PVS followed, if the test was again negative, by PVS combined with oral midodrine. Midodrine was administered at doses ranging from 5 mg to 25 mg using a stepwise approach. Of patients with a negative result with natural stimulation, 56% were salvaged by PVS, and when PVS was negative, another 22% were salvaged by midodrine combined with PVS. 10 The causes for anejaculation include psychogenic disorders, congenital disorders (obstructions of the efferent ducts or congenital absence of the vas deferens), SCI and various organic diseases (for example, diabetes mellitus, Parkinson's disease, multiple sclerosis and transverse myelitis). 
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Treatment modalities include psychotherapy, rectal probe EE, PVS and drug therapy. In a nice review article, Kamischke et al. 5 concluded that, in anejaculation, medical treatment shows low overall success rates compared with electrovibration stimulation and EE. However, EE mostly is used in case of infertility. In addition, adverse events, such as rectal injury and autonomic dysreflexia, are likely after EE. 16 For reversal of anejaculation in daily life, medical treatment is preferred. Drug therapy for patients who suffer from organic anejaculation but not SCI, has been exclusively with a-agonistic drugs (imipramine, ephedrine and pseudoephedrine). 5 Among the different a-agonistic medical treatments, milodrin is better than imipramine (P ¼ 0.008), pseudoephedrine (P ¼ 0.02) and ephedrine (P ¼ 0.044), in terms of the reversal of anejaculation. 5 Side effects of a-agonists for the treatment of anejaculation include various degrees of dizziness, sleep disturbances, weakness, restlessness, dry mouth, nausea and sweating. 17 Regardless of the mechanism of action, midodrine as a potential therapy for anejaculation has several advantages. It does not cross the blood-brain barrier and therefore does not have any side effects such as anxiety, agitation and insomnia common with other a-agonists. 18 Daily treatment strategy was used in this study rather than on-demand treatment. For reversal of the anejaculation, a-agonists are more effective over a few days rather than as a single dose before intercourse. 19 Treatment of an ejaculation should be etiology specific and address the issue of infertility in men desiring pregnancy. In the available literature, we could not find similar studies for comparison. Most reports with a-agonists are anecdotal case reports/series. Although midodrine treatment may not always produce AE, it can convert a substantial numbers of patients with lack of emission into one with RE. It can result in small amounts of viable sperm sufficient for use in some forms of artificial reproductive techniques in infertile couples. The advantages of oral therapy with midodrine include broad patient acceptance, ease of administration and relative efficacy. The disadvantage includes concomitant vasoconstrictive effect.
Conclusion
The results of this study are encouraging. In patients with organic anejaculation, but not in those with SCI, the administration of midodrine induces antegrade and/or retrograde ejaculation in more than 50% of patient. Further studies are needed to confirm the efficacy of this treatment. The current standard practice mandates for a more elaborate management of patients with anejaculation.
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